Google
ABSI — ABSCI CORP (Healthcare >> Biotechnology)
ABSI FAQ
What is ABSI's ROE?
ABSCI CORP reports a Return on Equity (ROE) of -68.87%.
What is ABSI's dividend yield?
ABSCI CORP offers a dividend yield of 0.00%.
What is ABSI's Deepscope Quality Score?
Deepscope rates ABSI's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy ABSI?
Deepscope's AI Timing Score for ABSI is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does ABSI belong to?
ABSCI CORP is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 7.34
Price
1.40
(23.57%)
Day Change
|
|
|---|
ABSI, ファンダメンタルスコアはnot good ( ファンダメンタル = 23) but テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
ROAがROEに比べて低い
Last-year ROA is lower than last-2-years ROA.
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.08 From 30 days period |
| News Score | 97 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 7.34 |
| PBV / Sector |
5.76 / 4.58
|
| Earning Per Share | -0.88 |
| PE / Sector |
N/A / 17.10
|
| PEG or PE/Growth / Sector |
N/A / 0.52
|
| Average 1M Daily Value |
28.74 M
GREAT
|
| Average 1W Daily Value |
43.54 M
GREAT
|
| Timing Factors |
|
100% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
56% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-05 09:12:37 |
| Symbol | ABSI |
| Name | ABSCI CORP |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 155.91 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 990.00 / 8,655.90 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 18105 SE Mill Plain Boulevard, Vancouver, WA, United States, 98683
Phone: 360 949 1041
Website: https://www.absci.com
Employees: 140
Sector: Healthcare >> Biotechnology
Description: Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
